**Journal of Trauma and Acute Care Surgery**

Enteral tranexamic acid attenuates vasopressor resistance and changes in α1-adrenergic receptor expression in hemorrhagic shock  
--Manuscript Draft--

<table>
<thead>
<tr>
<th>Manuscript Number:</th>
<th>JT-D-16-06042R1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full Title:</td>
<td>Enteral tranexamic acid attenuates vasopressor resistance and changes in α1-adrenergic receptor expression in hemorrhagic shock</td>
</tr>
<tr>
<td>Article Type:</td>
<td>Original Article</td>
</tr>
<tr>
<td>Section/Category:</td>
<td></td>
</tr>
<tr>
<td>Keywords:</td>
<td>Hemorrhagic shock; vasopressor resistance; tranexamic acid; Alpha-1 adrenergic receptor</td>
</tr>
</tbody>
</table>
| Corresponding Author: | Federico Aletti, Ph.D.  
Politecnico di Milano  
Milan, MI ITALY |
| Corresponding Author Secondary Information: | |
| Corresponding Author's Institution: | Politecnico di Milano |
| Corresponding Author's Secondary Institution: | |
| First Author:      | Marco Santamaria, M.Sc. |
| First Author Secondary Information: | |
| Order of Authors:  | Marco Santamaria, M.Sc.  
Federico Aletti, Ph.D.  
Joyce B Li  
Aaron Tan  
Monica Chang  
Jessica Leon  
Geert W Schmid-Schönbein, Ph.D.  
Erik B Kistler, M.D., Ph.D. |
| Order of Authors Secondary Information: | |
| Manuscript Region of Origin: | UNITED STATES |

*Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation*
Enteral tranexamic acid attenuates vasopressor resistance and changes in α1-adrenergic receptor expression in hemorrhagic shock

*Marco Santamaria¹, *Federico Aletti²¹, Joyce B. Li¹, Aaron Tan¹, Monica Chang¹, Jessica Leon¹, Geert W. Schmid-Schönbein¹ and Erik B. Kistler³

1 Department of Bioengineering, University of California San Diego, San Diego, CA, U.S.A.

2 Dipartimento di Elettronica, Informazione e Bioingegneria, Politecnico di Milano, Milan, Italy

3 Department of Anesthesiology & Critical Care, VA San Diego Healthcare System

Running Head: α₁ receptor changes in hemorrhagic shock

Keywords: Hemorrhagic Shock; vasopressor resistance; tranexamic acid; Alpha-1 adrenergic receptor.

Corresponding Author:

Federico Aletti, PhD
Dipartimento di Elettronica, Informazione e Bioingegneria, Politecnico di Milano
Piazza Leonardo da Vinci, 32 – 20133 – Milan, Italy.
E-mail address: federico.aletti@polimi.it

*These authors contributed equally to the work as co-first authors.
ABSTRACT

BACKGROUND: Irreversible hemorrhagic shock is characterized by hyporesponsiveness to vasopressor and fluid therapy. Little is known, however, about the mechanisms that contribute to this phenomenon. Previous studies have shown that decreased intestinal perfusion in hemorrhagic shock leads to proteolytically-mediated increases in gut permeability, with subsequent egress of vasoactive substances systemically. Maintenance of blood pressure is achieved in part by $\alpha_1$ receptor modulation, which may be affected by vasoactive factors; we thus hypothesized that decreases in hemodynamic stability and vasopressor response in shock can be prevented by enteral protease inhibition. METHODS: Rats were exposed to experimental hemorrhagic shock (35 mmHg mean arterial blood pressure for 2 hrs, followed by reperfusion for 2 hrs) and challenged with phenylephrine (2 µg/kg) at discrete intervals to measure vasopressor responsiveness. A second group of animals received enteral injections with the protease inhibitor tranexamic acid (TXA) (127 mM) along the small intestine and cecum one hour following induction of hemorrhagic shock.

RESULTS: Blood pressure response (duration and amplitude) to phenylephrine after reperfusion was significantly attenuated in animals subjected to hemorrhagic shock compared to baseline and control non-shocked animals, and was restored to near baseline by enteral TXA. Arteries from shocked animals also displayed decreased $\alpha_1$ receptor density with restoration to baseline following enteral TXA treatment. In vitro, rat shock plasma decreased $\alpha_1$ receptor density in smooth muscle cells, which was also abrogated by enteral TXA treatment.

CONCLUSIONS: Results from this study demonstrate that experimental hemorrhagic shock leads to decreased response to the $\alpha_1$-selective agonist phenylephrine and decreased $\alpha_1$ receptor density via circulating shock factors. These changes are mitigated by enteral TXA with
correspondingly improved hemodynamics. Proteolytic inhibition in the lumen of the small intestine improves hemodynamics in hemorrhagic shock, possibly by restoring α₁ adrenergic functionality necessary to maintain systemic blood pressure and perfusion.

LEVEL OF EVIDENCE: N/A

Acknowledgement: Supported by NIH grant GM 85072, Career Development Award (CDA2) 1IK2BX001277-01A1 from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, GM 85072, the “CelSys Shock” Marie Curie International Outgoing Fellowship (PIOF-GA-2012-328796) of the European Union in support of the corresponding author, and the “ShockOmics” Project of the European Union (Grant#602706).
BACKGROUND

One of the most challenging problems in the care of patients suffering from circulatory shock is vasopressor resistance, which is characterized by hyporesponsiveness to the infusion of vasoactive drugs required to maintain adequate hemodynamics. The mortality of patients in shock requiring vasopressors is high (> 50%) and hypotension characterizes the majority of deaths despite vasopressor support.1-3

While the cause of hypotension that typically accompanies and characterizes circulatory shock can be attributed to vasodilation generated by the strong inflammatory response occurring in shock, no consensus exists as to the mechanisms for vasopressor hyporeactivity. Several hypotheses have been postulated to account for vasopressor resistance. For instance, it is known that systemic vasopressin levels are reduced in shock4 and that nitric oxide production may be increased and contributes to vasodilation and cardiac dysfunction.5 However, clinical trials have proposed therapies interfering with these pathways without success in reducing mortality to vasopressor resistance-induced refractory shock.6, 7

One potential mechanism contributing to hyporesponsiveness to vasopressor administration in hemorrhagic shock may be altered function of the vascular α1 adrenergic receptor, a Gq-coupled receptor which is a fundamental controller of vascular tone and determinant of systemic vascular resistance (SVR). Activation of α1 increases intracellular calcium and subsequent smooth muscle contraction resulting in vasoconstriction of the vasculature. Although the α1 adrenergic receptor is also found in the heart, α1 appears to be almost exclusively involved in the maintenance of vascular tone.8, 9 SVR and thus blood pressure, when exogenously supported in the critical care setting, are with the exception of
vasopressin, controlled by agents that act on the $\alpha_1$ adrenergic receptor (phenylephrine, epinephrine, norepinephrine, dopamine). Therefore, decreased responsiveness to this receptor has important implications for available treatment options and outcome.

It has been previously shown that hemorrhagic shock may reduce the surface density of important transmembrane receptors, such as the insulin receptor,\textsuperscript{10} thus reducing the response to insulin (insulin resistance) in shock. We hypothesize that decreased transmembrane receptor density in shock may result, either directly or indirectly, from uncontrolled proteolytic activity, possibly by digestive pancreatic enzymes from the small intestine.\textsuperscript{11} Integrity of the intestinal mucous layer is compromised in circulatory shock,\textsuperscript{12-14} and a consequence of the breakdown of this barrier may be leakage of digestive enzymes and inflammatory products from the intestinal lumen into the bloodstream.\textsuperscript{15} Once in the systemic circulation, these mediators may lead to remote organ failure and mortality (autodigestion).\textsuperscript{11}

The objective of this study was to investigate a new hypothesis for vasopressor resistance in shock, by analyzing alterations in $\alpha_1$ adrenergic receptor expression in a rat model of hemorrhagic shock. We also tested a therapeutic intervention aimed at maintaining vasopressor responsiveness in hemorrhagic shock, by the administration of tranexamic acid (TXA) in the intestinal lumen. Used intravenously to decrease bleeding predominantly due to its actions as a plasminogen inhibitor,\textsuperscript{16} TXA also can function as a trypsin inhibitor and has been shown to improve outcomes in shock when given enterally,\textsuperscript{15} in part by protecting the gut mucosal barrier from proteolytic degradation.\textsuperscript{17,18}
METHODS

A. Experimental Protocol

All animal protocols were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) at the University of California, San Diego and conform to the Guide for the Care and Use of Laboratory Animals, 8th edition, by the National Institutes of Health (2011). Twenty-four non-fasted male Wistar rats (300-450 g, Harlan Laboratories, Inc., Indianapolis, IN) were randomly assigned to either Control (no shock) (n=6), hemorrhagic shock (HS) (n=6), hemorrhagic shock with enteral tranexamic acid treatment (HS + TXA) (n=6), or hemorrhagic shock with enteral Golytely® (HS + Vehicle) as a hemorrhagic shock control (n=6). All rats were anesthetized (xylazine, 4 mg/kg; ketamine 75 mg/kg IM) with supplemental anesthesia administered intravenously as needed (xylazine, 4 mg/kg; ketamine 7.5 mg/kg IV). The right femoral vein and artery were cannulated for blood withdrawal and intravenous supplemental anesthesia and continuous monitoring of arterial pressure, respectively. Body temperature was maintained at 37°C via water-heated support and heat blanket.

Control animals were monitored for 4 hours under anesthesia without other interventions. HS and HS + TXA animals were allowed 5 min for hemodynamic stabilization after induction of anesthesia and vascular line placement. All animals were heparinized (1 unit heparin/cc total blood volume, estimated at 6% body weight, intravenously) to allow for blood withdrawal. Hemorrhage was induced by blood withdrawal through the femoral vein (0.5 cc/min) to a target mean arterial blood pressure (MABP) of 35 mmHg. MABP was maintained between 30 and 40 mmHg for 2 hours, after which time the withdrawn blood was returned to the animals (0.5 cc/min). Maintenance of MABP during the ischemic period was accomplished by the removal or
return of small aliquots of blood as necessary to ensure maintenance of the targeted pressure. The shed blood was maintained at room temperature (22°C) during hypovolemia, and warmed to 37°C prior to return to the animals. Animals were monitored for an additional two hours upon completion of blood return.

To test for vascular responsiveness the selective \( \alpha_1 \) adrenergic agonist phenylephrine (2 \( \mu \)g/kg) was administered as intravenous bolus (0.1 ml) once before hemorrhage to obtain baseline response and again serially at 30 minutes, 90 minutes, and 120 minutes after the start of reperfusion. Total deflection of MABP from baseline (\( \Delta \)MABP), i.e. difference between maximum value of MABP after challenge and value before challenge, as well as duration of response (DOR) (time to return to within 3% of baseline) were measured as indices of vascular response to phenylephrine. In addition, % changes in the area-under-the-curve (\( \Delta \)AUC) from baseline were calculated for all animals and all groups as another method for understanding and interpreting the data.

In HS + TXA animals, tranexamic acid (127 mM TXA, Cyclokapron, Pfizer) was administered at 1 hour into the hypovolemic period into the lumen of the small intestine via sequential injections (BD Sub-Q 26G 5/8 PrecisionGlide Needle, Becton Dickinson & Co.) spaced approximately 5 cm apart for an average of 8 injections longitudinally along its length. GoLytely® (0.14 g /ml 0.9% sterile water) was used as carrier solution. A total fluid volume of 15 ml was injected into the lumen of the small intestine. An additional 2 ml of TXA in vehicle was injected into the cecum. The dosage of the TXA was based on previously determined effective concentrations.\(^{15}\) A second group of animals (HS + Vehicle) undergoing hemorrhagic shock was instrumented as above and enteral injections of carrier solution only (GoLytely®) were performed as an additional hemorrhagic shock control. Hemodynamics from this group
were indistinguishable from those of the HS group, and subsequent analyses were carried out on the HS animals (Figure 1). HS, HS + TXA, and HS + Vehicle groups were subjected to phenylephrine challenge (2 µg/kg) as described above once before hemorrhage and at 30, 90, and 120 min after the start of the reperfusion period.

Following a two-hour observation period after return of shed blood (Reperfusion), animals were euthanized with B-Euthanasia (120 mg/kg). Death was confirmed by loss of signal on blood pressure monitor followed by bilateral thoracotomy.

B. Tissue Collection

Renal arteries were harvested following laparotomy, gently rinsed to remove residual blood and homogenized in lysis buffer (ThermoScientific). Homogenates were treated with the addition of a protease inhibitor cocktail (1:25, Roche) for Western blot analysis. Arterial homogenates were stored at −80°C for later use. Right femoral arteries were gently excised, washed four times in 10% formalin for 15 min each, and placed directly into 10% formalin and stored at room temperature for immunohistochemical analysis (IHC).

C. Western Blot Detection of Arterial α₁ Adrenergic Receptor

Renal artery homogenate samples from each animal (60 µl/sample; 0.5 µg/µl) were separated by SDS-PAGE. For Western blotting, proteins were transferred to a 0.45 µm pore size nitrocellulose membrane (Bio-Rad Laboratories, Inc., Hercules, CA; #162-0097). Following blockade with 5% nonfat dry milk in buffer (Tris-Buffered Saline and Tween 20, TBST),
primary antibodies against \( \alpha_{1D} \) adrenergic receptor (\( \alpha_1R \)) (H-142, 1:300, sc-10721, Santa Cruz Biotechnology, Santa Cruz, CA) were applied. \( \beta \)-actin (C4, 1:100, sc-47778, Santa Cruz Biotechnology, Santa Cruz, CA) was used as loading control. Corresponding secondary antibodies were applied at 1:5000 dilution. Antibodies were diluted in TBST. Supersignal West Pico Chemiluminescent substrate (ThermoFisher Scientific, Waltham, MA; #34096) was used for imaging. Molecular weights were estimated by use of an electrophoresis marker (Sigma Aldrich, C1992). Gels were digitized and bands were analyzed by densitometry in ImageJ, and results are reported as ratios of \( \alpha_1R / \beta \)-actin.

**D. Immunohistochemistry (IHC) Detection of Arterial \( \alpha_{1} \) Adrenergic Receptor**

Femoral arteries were resected, formalin fixed, and mounted longitudinally for sectioning. 30 µm sections were made along the length of the artery and placed in 10% formalin overnight. Sections were rinsed in distilled water to remove residual formalin. Endogenous peroxidase activity was removed with Bloxall (Vector Laboratories, Burlingame, CA, SP-6000). 2.5% normal horse serum (Vector Laboratories, Burlingame, CA, S-2012) was then used as a blocking reagent followed by primary antibody incubation with \( \alpha_{1D} \) antibody (1:200, sc-10721, Santa Cruz Biotechnology, Santa Cruz, CA) for 90 min. Sections were incubated for 30 min in ImmPRESS anti-rabbit Ig (Vector Laboratories, Burlingame, CA, MP-7401) and ImmPACT DAB (Vector Laboratories, Burlingame, CA, SK-4105) was used for staining. Sections were mounted using Vectamount (Vector Laboratories, Burlingame, CA, H-5000). Bright-field imaging was carried out at 10X objective magnification. Images were digitized to 8-bit format and measurements were taken of smooth muscle regions in each section (6 measurements/image,
10 images/animal). All analysis was performed on ImageJ. Precautions were taken to assure that all IHC steps were carried out under standard conditions to allow quantitative comparison with digital image analysis.

**E. Immunocytochemistry of Smooth Muscle Cells Following Rat Plasma Incubation (ICC)**

Blood samples from Control (n = 6), HS (n = 6), HS + TXA (n = 6), and HS + Vehicle (n = 6) rats were drawn and blood was centrifuged at 600g for 10 min to achieve plasma separation. Human carotid smooth muscle cells (SMC) (HCTASMC; Cell Applications, San Diego, CA) were cultured in growth medium (311D-250; Cell Applications, San Diego, CA) at 37 °C in an atmosphere of 5% CO₂ and allowed to reach approximately 100% confluence before being exposed to either starvation medium (310-500: Cell Applications, San Diego, CA), or plasma from Control, HS, HS +TXA, or HS + Vehicle animals. SMCs were incubated in the presence of plasma variant or starvation medium for 3 hours at 37°C. Cells were starved in serum free media for 12 h prior to experimentation and plasma samples were diluted in a 1:5 ratio in starvation medium immediately prior to incubation. **Added plasma was normalized to volume rather than protein content.** Cells were stained as described above for rat femoral artery sections. Images were acquired at 10X objective magnification, digitized to 8-bit format and measurements were taken as the average intensity for individual cells. All analysis was performed on ImageJ. Precautions were taken to assure that all ICC steps were carried out under standard conditions to allow quantitative comparison with digital image analysis.

**F. Statistical Analysis**
Data are presented as mean ± standard deviation (SD) unless otherwise noted. One-way analysis of variance (ANOVA) was used where appropriate to evaluate the differences between groups with a post-hoc Tukey correction. All analyses were performed using Graphpad (Graphpad Software Inc., La Jolla, CA). A value of p < 0.05 was considered statistically significant for all tests.

RESULTS

A. Blood Pressure Response to Enteral TXA Treatment

All groups subjected to HS were maintained at similar systemic blood pressures during hypovolemia. After return of the shed blood, pressure was transiently restored, before dropping significantly in the HS and HS + Vehicle groups (Figure 1). The animal group treated enterally with TXA (HS + TXA) displayed significantly higher MABP after reperfusion compared to both shock groups.

B. Systemic Vasopressor Response

Vasopressor responsiveness to phenylephrine challenge in vivo during hemorrhagic shock was assessed by ΔMABP and DOR at baseline, and 30, 90 and 120 minutes after the start of reperfusion (Figure 2). There were no significant differences between groups for either ΔMABP or DOR at baseline. At 30 minutes after reperfusion there was a significant decrease in DOR for the HS + Vehicle group (p<0.01) and ΔMABP for both HS and HS + Vehicle groups compared to baseline (p<0.01, 0.0001, respectively) (Figures 3 and 4). This decrement in function in the untreated HS groups continued for the duration of the experiment in both HS and HS + Vehicle
groups (90 min: ΔMABP (p< 0.001, 0.01 respectively), DOR (p< 0.05), and 120 min: ΔMABP (p<0.05, 0.01 respectively), and DOR (p< 0.01)). At no time point during the study did ΔMABP or DOR in the HS + TXA group differ significantly from baseline. Differences in the changes in the AUC (ΔAUC) from baseline (100%) showed a trend towards significance between the HS + Vehicle (26%, p=0.05) and HS groups (37%, p=0.064) vs. HS + TXA (71% of baseline response) at 90 minutes with significant differences between groups at 120 minutes: HS + Vehicle (23%) and HS (26%) vs. HS + TXA (71%, p<0.01 for both groups).

C. α₁ Adrenergic Receptor Levels

The α₁ adrenergic receptor was examined by Western blot to determine whether there were changes in α₁ receptor density in shock and whether these levels were preserved after treatment with enteral TXA. α₁ receptor density was markedly decreased (p<0.01) by HS as measured by Western blot (Figure 5A) but maintained near Control levels by enteral treatment with TXA. Measurements of α₁ receptor density were confirmed using IHC combined with digital image analysis (Figure 5C), where receptor levels as detected by immunolabeling were also significantly decreased in HS compared to Control (p < 0.01). Enteral treatment with TXA resulted in light absorbance levels similar to those of the Control group.

D. Human Carotid SMC α₁ Adrenergic Receptor Levels

SMCs were examined for α₁ using ICC (Figure 6). α₁ receptor density was significantly decreased in HS and HS + Vehicle compared to Control groups (p < 0.001, p < 0.05, respectively), while incubation with plasma from the HS + TXA group resulted in levels similar
to Control. $\alpha_1$ receptor levels from the HS + Vehicle and HS groups did not differ significantly from each other.

**DISCUSSION**

Fulminate decompensated hemorrhagic shock (Class IV),\textsuperscript{19} characterized by limited responsiveness to fluid bolus and vasopressor therapy, carries a poor prognosis, in part because no effective interventions exist. Lack of responsiveness to vasopressors and failure to maintain vascular tone, commonly described in septic shock, are not well documented for hemorrhagic shock, and although several hypotheses have been proposed, there currently exists no consensus as to mechanism.\textsuperscript{20} To study this problem, we examined the role of the $\alpha_1$ adrenergic receptor in experimental hemorrhagic shock. The $\alpha_1$ receptor is the archetypical adrenergic receptor most responsible for maintaining systemic vascular tone (vasoconstriction) and we hypothesized that failure of this receptor, either through reduced density or function, results in decreased vascular tone and subsequent hemodynamic collapse in hemorrhagic shock.\textsuperscript{8} Furthermore, we hypothesized that enteral treatment with tranexamic acid (TXA), a mild trypsin inhibitor,\textsuperscript{21} would lead to improved hemodynamics in hemorrhagic shock, in part by maintaining $\alpha_1$ receptor activity by prevention of proteolytically-mediated processes. The mechanisms of action by which enteral TXA is effective in experimental hemorrhagic shock appears unrelated to TXA’s well-known clinical role as an antifibrinolytic. Although IV TXA has some efficacy in hemorrhagic shock,\textsuperscript{16} this has not been consistently reported.\textsuperscript{22} Other protease inhibitors with differing effects on the coagulation system have also been found to be effective when given enterally to treat experimental shock,\textsuperscript{23, 24} and the limited patient information on the subject appears to support the
hypothesis that the protease inhibitors must be given enterally to display marked clinical improvement.  

This study confirms previous reports that enteral inhibition with TXA leads to improved hemodynamics in experimental hemorrhagic shock.\textsuperscript{15} Using phenylephrine as a probe for $\alpha_1$ adrenergic receptor responsiveness, we report here that systemic sensitivity to this receptor decreases in experimental hemorrhagic shock with concomitant decrements in systemic pressure maintenance. The decrease in hemodynamic response is manifest as measured by attenuated changes in mean systemic blood pressure ($\Delta$MABP) and in the duration of response (DOR) to the pressor agent phenylephrine, as well as by changes in the total hemodynamic effectiveness of phenylephrine ($\Delta$AUC). This reduction in hemodynamic responsiveness begins early in the reperfusion period and continues unabated through the end of the experiment. Western blot analysis and IHC confirm decreased $\alpha_1$ adrenergic receptor density in hemorrhagic shock; the decrement in density appears to be a mechanism by which $\alpha_1$ receptor-mediated hyporesponsiveness is mediated. This result is consistent with reports from other investigators on adrenergic function in shock, which appears to be predominantly related to changes in receptor density rather than function.\textsuperscript{26}

The mechanisms by which vascular $\alpha_1$ adrenergic receptor density is modulated in shock are unknown, but results from our study demonstrate that circulating factors in the blood may be operant. These circulating mediators may include digestive pancreatic proteases\textsuperscript{15} and products of proteolysis that either directly,\textsuperscript{27} or indirectly through vasoactive degradation products\textsuperscript{14} affect receptor function, and thus vascular responsiveness. Supporting this hypothesis are our current findings that enteral TXA restores receptor levels to baseline concentrations with commensurate improvements in hemodynamics in experimental hemorrhagic shock by protecting the ischemic
small bowel from proteolytic degradation;\textsuperscript{11, 12, 15} this protection is not seen with intravenous protease inhibitor treatment.\textsuperscript{28}

There are several limitations to this study. Among these is the lack of a detailed described mechanism by which enteral TXA inhibition in the bowel restores $\alpha_1$ receptor function systemically. Previous studies have demonstrated increased survival after experimental shock with enteral protease inhibition,\textsuperscript{15} but not with intravenous protease inhibition.\textsuperscript{28, 29} The reasons for this are two-fold: first, the high concentrations of proteolytic enzymes in the bowel (millimolar range) can only be overcome by high concentrations of inhibitor in the bowel lumen, which is not feasible in the systemic circulation. Second, and more importantly, by limiting proteolytic degradation of the bowel mucosa and resulting permeability changes,\textsuperscript{13, 17, 18, 30} enteral protease inhibition prevents the systemic egress of non-protease gut mediators that might otherwise affect $\alpha_1$ receptor function and result in subsequent hypotension. Further studies are necessary to identify the mediators and mechanisms responsible for this phenomenon. Likewise, although changes in $\alpha_1$ receptor responsiveness appear to be secondary to changes in density as shown by Western blot and IHC analysis, the possibility of abnormal $\alpha_1$ receptor binding or malfunction in hemorrhagic shock cannot be excluded. Finally, it is acknowledged that other receptors, both adrenergic (e.g., $\beta_1$, $\beta_2$) and otherwise (e.g., vasopressin), are also operant and may be affected in hemorrhagic shock; further studies are necessary to clarify the roles of these receptors in this condition and the possible effect of enteral TXA in modulating them.

In conclusion, this study proposes a possible mechanism for vasopressor resistance-induced refractory shock by demonstrating that hemorrhagic shock decreases $\alpha_1$ adrenergic receptor responsiveness and density. Decrements in $\alpha_1$ adrenergic receptor activity and concentrations are mitigated by enteral treatment with TXA, with resultant improved
hemodynamics and vascular responsiveness. Restoration of $\alpha_1$ receptor density and functionality may be a key mechanism by which enteral TXA improves systemic blood pressure and survival in experimental hemorrhagic shock.

**AUTHOR CONTRIBUTION STATEMENT**

MS, FA, JBL, AT, MC, and JL participated in data acquisition, analysis and experimental design; FA, GWS and EBK participated in experimental design, data analysis, data interpretation and drafting of the manuscript.
REFERENCES


**FIGURE LEGENDS**

**Figure 1**
Mean arterial blood pressure (MABP) of Control, Hemorrhagic Shock (HS), Hemorrhagic Shock + Enteral Tranexamic Acid (HS + TXA), and Hemorrhagic Shock + Vehicle (HS + Vehicle) groups. MABP was decreased to a mean of 35 mmHg over several minutes by the serial withdrawal of small aliquots of blood (0.5 ml/min). Reperfusion was carried out in analogous fashion by slow reinfusion of shed blood (0.5 ml/min). **p < 0.01 Control vs. HS + TXA and #p < 0.0001 HS, HS + Vehicle vs. HS + TXA and Control; #p < 0.0001 Control vs. HS, HS + Vehicle, HS + TXA during ischemia period as per experimental design. There were no statistical differences between HS and HS + Vehicle groups at any time points. Results shown as Mean ± SD.

**Figure 2**
Representative hemodynamic response to phenylephrine challenge (ΔMABP) at 120 min after start of reperfusion for a single animal in each group.

**Figure 3**
(A) Average absolute change in MABP (ΔMABP) per group over time in response to phenylephrine challenge (Mean ± SD). (B) ΔMABP response to phenylephrine challenge 30 min after start of reperfusion, (C) ΔMABP response to phenylephrine challenge 90 min after start of reperfusion, (D) ΔMABP response to phenylephrine challenge 120 min after start of reperfusion. *p < 0.05 Control vs. HS, **p < 0.01 Control vs. HS, HS + Vehicle, ***p < 0.001 Control vs. HS, ****p < 0.0001 Control vs HS + Vehicle. Results plotted as Mean ± SD.

**Figure 4**
(A) Average response duration to phenylephrine challenge (DOR) per group over time (Mean ± SD). (B) DOR to phenylephrine challenge 30 min after start of reperfusion, (C) DOR to phenylephrine challenge 90 min after start of reperfusion, (D) DOR to phenylephrine challenge 120 min after start of reperfusion. *p < 0.05 Control vs. HS, HS + Vehicle, **p < 0.01 Control vs. HS, HS + Vehicle. Results plotted as Mean ± SD.

**Figure 5**
(A) α₁D renal artery band density by Western blot with representative α₁D renal artery band (α-1 AR). The average of the control band densities was used as a reference. β-actin is shown as a loading control for the same animals. (B) Histogram of the average relative band intensities per
group expressed as ratios of $\alpha_1$R/$\beta$-actin (n=6 animals/group). *p < 0.05, HS vs. HS + TXA; **p < 0.01, Control vs. HS. Results plotted as Mean ± SD. (C) Representative femoral artery sections labeled for $\alpha_{1D}$. Insets indicate sample smooth muscle regions of interest (squared boxes) both before and after 8-bit conversion. (D) Histogram of labeling density values in digital units. Scale bar is = 100 microns. **p < 0.01 Control vs. HS, *p<0.05 HS + TXA vs all other groups. Results plotted as Mean ± SD.

Figure 6

(A) Human carotid SMCs labeled for $\alpha_{1D}$ adrenergic receptor following 3 hour incubation with rat plasma, normalized with respect to added plasma volume. Histograms display labeling density values in digital units. Scale bar is = 10 microns. *p<0.05 Control vs. HS + Vehicle, ***p < 0.001 Control vs. HS, ***p<0.001 HS + TXA vs. HS + Vehicle, ****p<0.0001 HS + TXA vs. HS. Results plotted as Mean ± SD.
Enteral tranexamic acid attenuates vasopressor resistance and changes in $\alpha_1$-adrenergic receptor expression in hemorrhagic shock

*Marco Santamaria$^1$, *Federico Aletti$^{2,1}$, Joyce B. Li$^1$, Aaron Tan$^1$, Monica Chang$^1$, Jessica Leon$^1$, Geert W. Schmid-Schönbein$^1$ and Erik B. Kistler$^3$

$^1$ Department of Bioengineering, University of California San Diego, San Diego, CA, U.S.A.

$^2$ Dipartimento di Elettronica, Informazione e Bioingegneria, Politecnico di Milano, Milan, Italy

$^3$ Department of Anesthesiology & Critical Care, VA San Diego Healthcare System

Running Head: $\alpha_1$ receptor changes in hemorrhagic shock

Keywords: Hemorrhagic Shock; vasopressor resistance; tranexamic acid; Alpha-1 adrenergic receptor.

Corresponding Author:

Federico Aletti, PhD
Dipartimento di Elettronica, Informazione e Bioingegneria, Politecnico di Milano
Piazza Leonardo da Vinci, 32 – 20133 – Milan, Italy.
E-mail address: federico.aletti@polimi.it

*These authors contributed equally to the work as co-first authors.
ABSTRACT

BACKGROUND: Irreversible hemorrhagic shock is characterized by hyporesponsiveness to vasopressor and fluid therapy. Little is known, however, about the mechanisms that contribute to this phenomenon. Previous studies have shown that decreased intestinal perfusion in hemorrhagic shock leads to proteolytically-mediated increases in gut permeability, with subsequent egress of vasoactive substances systemically. Maintenance of blood pressure is achieved in part by α₁ receptor modulation, which may be affected by vasoactive factors; we thus hypothesized that decreases in hemodynamic stability and vasopressor response in shock can be prevented by enteral protease inhibition. METHODS: Rats were exposed to experimental hemorrhagic shock (35 mmHg mean arterial blood pressure for 2 hrs, followed by reperfusion for 2 hrs) and challenged with phenylephrine (2 µg/kg) at discrete intervals to measure vasopressor responsiveness. A second group of animals received enteral injections with the protease inhibitor tranexamic acid (TXA) (127 mM) along the small intestine and cecum one hour following induction of hemorrhagic shock.

RESULTS: Blood pressure response (duration and amplitude) to phenylephrine after reperfusion was significantly attenuated in animals subjected to hemorrhagic shock compared to baseline and control non-shocked animals, and was restored to near baseline by enteral TXA. Arteries from shocked animals also displayed decreased α₁ receptor density with restoration to baseline following enteral TXA treatment. In vitro, rat shock plasma decreased α₁ receptor density in smooth muscle cells, which was also abrogated by enteral TXA treatment.

CONCLUSIONS: Results from this study demonstrate that experimental hemorrhagic shock leads to decreased response to the α₁-selective agonist phenylephrine and decreased α₁ receptor density via circulating shock factors. These changes are mitigated by enteral TXA with
correspondingly improved hemodynamics. Proteolytic inhibition in the lumen of the small intestine improves hemodynamics in hemorrhagic shock, possibly by restoring α₁ adrenergic functionality necessary to maintain systemic blood pressure and perfusion.

LEVEL OF EVIDENCE: N/A

Acknowledgement: Supported by NIH grant GM 85072, Career Development Award (CDA2) 1IK2BX001277-01A1 from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, GM 85072, the “CelSys Shock” Marie Curie International Outgoing Fellowship (PIOF-GA-2012-328796) of the European Union in support of the corresponding author, and the “ShockOmics” Project of the European Union (Grant#602706).
BACKGROUND

One of the most challenging problems in the care of patients suffering from circulatory shock is vasopressor resistance, which is characterized by hyporesponsiveness to the infusion of vasoactive drugs required to maintain adequate hemodynamics. The mortality of patients in shock requiring vasopressors is high (> 50%) and hypotension characterizes the majority of deaths despite vasoppressor support.1-3

While the cause of hypotension that typically accompanies and characterizes circulatory shock can be attributed to vasodilation generated by the strong inflammatory response occurring in shock, no consensus exists as to the mechanisms for vasopressor hyporeactivity. Several hypotheses have been postulated to account for vasopressor resistance. For instance, it is known that systemic vasopressin levels are reduced in shock4 and that nitric oxide production may be increased and contributes to vasodilation and cardiac dysfunction.5 However, clinical trials have proposed therapies interfering with these pathways without success in reducing mortality to vasopressor resistance-induced refractory shock.6, 7

One potential mechanism contributing to hyporesponsiveness to vasopressor administration in hemorrhagic shock may be altered function of the vascular α1 adrenergic receptor, a Gq-coupled receptor which is a fundamental controller of vascular tone and determinant of systemic vascular resistance (SVR). Activation of α1 increases intracellular calcium and subsequent smooth muscle contraction resulting in vasoconstriction of the vasculature. Although the α1 adrenergic receptor is also found in the heart, α1 appears to be almost exclusively involved in the maintenance of vascular tone.8, 9 SVR and thus blood pressure, when exogenously supported in the critical care setting, are with the exception of
vasopressin, controlled by agents that act on the $\alpha_1$ adrenergic receptor (phenylephrine, epinephrine, norepinephrine, dopamine). Therefore, decreased responsiveness to this receptor has important implications for available treatment options and outcome.

It has been previously shown that hemorrhagic shock may reduce the surface density of important transmembrane receptors, such as the insulin receptor, thus reducing the response to insulin (insulin resistance) in shock. We hypothesize that decreased transmembrane receptor density in shock may result, either directly or indirectly, from uncontrolled proteolytic activity, possibly by digestive pancreatic enzymes from the small intestine. Integrity of the intestinal mucous layer is compromised in circulatory shock, and a consequence of the breakdown of this barrier may be leakage of digestive enzymes and inflammatory products from the intestinal lumen into the bloodstream. Once in the systemic circulation, these mediators may lead to remote organ failure and mortality (autodigestion).

The objective of this study was to investigate a new hypothesis for vasopressor resistance in shock, by analyzing alterations in $\alpha_1$ adrenergic receptor expression in a rat model of hemorrhagic shock. We also tested a therapeutic intervention aimed at maintaining vasopressor responsiveness in hemorrhagic shock, by the administration of tranexamic acid (TXA) in the intestinal lumen. Used intravenously to decrease bleeding predominantly due to its actions as a plasminogen inhibitor, TXA also can function as a trypsin inhibitor and has been shown to improve outcomes in shock when given enterally, in part by protecting the gut mucosal barrier from proteolytic degradation.
METHODS

A. Experimental Protocol

All animal protocols were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) at the University of California, San Diego and conform to the Guide for the Care and Use of Laboratory Animals, 8th edition, by the National Institutes of Health (2011). Twenty-four non-fasted male Wistar rats (300-450 g, Harlan Laboratories, Inc., Indianapolis, IN) were randomly assigned to either Control (no shock) (n=6), hemorrhagic shock (HS) (n=6), hemorrhagic shock with enteral tranexamic acid treatment (HS + TXA) (n=6), or hemorrhagic shock with enteral Golytely® (HS + Vehicle) as a hemorrhagic shock control (n=6). All rats were anesthetized (xylazine, 4 mg/kg; ketamine 75 mg/kg IM) with supplemental anesthesia administered intravenously as needed (xylazine, 4 mg/kg; ketamine 7.5 mg/kg IV). The right femoral vein and artery were cannulated for blood withdrawal and intravenous supplemental anesthesia and continuous monitoring of arterial pressure, respectively. Body temperature was maintained at 37°C via water-heated support and heat blanket.

Control animals were monitored for 4 hours under anesthesia without other interventions. HS and HS + TXA animals were allowed 5 min for hemodynamic stabilization after induction of anesthesia and vascular line placement. All animals were heparinized (1 unit heparin/cc total blood volume, estimated at 6% body weight, intravenously) to allow for blood withdrawal. Hemorrhage was induced by blood withdrawal through the femoral vein (0.5 cc/min) to a target mean arterial blood pressure (MABP) of 35 mmHg. MABP was maintained between 30 and 40 mmHg for 2 hours, after which time the withdrawn blood was returned to the animals (0.5 cc/min). Maintenance of MABP during the ischemic period was accomplished by the removal or
return of small aliquots of blood as necessary to ensure maintenance of the targeted pressure. The shed blood was maintained at room temperature (22°C) during hypovolemia, and warmed to 37°C prior to return to the animals. Animals were monitored for an additional two hours upon completion of blood return.

To test for vascular responsiveness the selective α₁ adrenergic agonist phenylephrine (2 µg/kg) was administered as intravenous bolus (0.1 ml) once before hemorrhage to obtain baseline response and again serially at 30 minutes, 90 minutes, and 120 minutes after the start of reperfusion. Total deflection of MABP from baseline (ΔMABP), i.e. difference between maximum value of MABP after challenge and value before challenge, as well as duration of response (DOR) (time to return to within 3% of baseline) were measured as indices of vascular response to phenylephrine. In addition, % changes in the area-under-the-curve (ΔAUC) from baseline were calculated for all animals and all groups as another method for understanding and interpreting the data.

In HS + TXA animals, tranexamic acid (127 mM TXA, Cyclokapron, Pfizer) was administered at 1 hour into the hypovolemic period into the lumen of the small intestine via sequential injections (BD Sub-Q 26G 5/8 PrecisionGlide Needle, Becton Dickinson & Co.) spaced approximately 5 cm apart for an average of 8 injections longitudinally along its length. GoLytely® (0.14 g /ml 0.9% sterile water) was used as carrier solution. A total fluid volume of 15 ml was injected into the lumen of the small intestine. An additional 2 ml of TXA in vehicle was injected into the cecum. The dosage of the TXA was based on previously determined effective concentrations. A second group of animals (HS + Vehicle) undergoing hemorrhagic shock was instrumented as above and enteral injections of carrier solution only (GoLytely®) were performed as an additional hemorrhagic shock control. Hemodynamics from this group
were indistinguishable from those of the HS group, and subsequent analyses were carried out on the HS animals (Figure 1). HS, HS + TXA, and HS + Vehicle groups were subjected to phenylephrine challenge (2 µg/kg) as described above once before hemorrhage and at 30, 90, and 120 min after the start of the reperfusion period.

Following a two-hour observation period after return of shed blood (Reperfusion), animals were euthanized with B-Euthanasia (120 mg/kg). Death was confirmed by loss of signal on blood pressure monitor followed by bilateral thoracotomy.

B. Tissue Collection

Renal arteries were harvested following laparotomy, gently rinsed to remove residual blood and homogenized in lysis buffer (ThermoScientific). Homogenates were treated with the addition of a protease inhibitor cocktail (1:25, Roche) for Western blot analysis. Arterial homogenates were stored at −80°C for later use. Right femoral arteries were gently excised, washed four times in 10% formalin for 15 min each, and placed directly into 10% formalin and stored at room temperature for immunohistochemical analysis (IHC).

C. Western Blot Detection of Arterial α₁ Adrenergic Receptor

Renal artery homogenate samples from each animal (60 µl/sample; 0.5 µg/µl) were separated by SDS-PAGE. For Western blotting, proteins were transferred to a 0.45 µm pore size nitrocellulose membrane (Bio-Rad Laboratories, Inc., Hercules, CA; #162-0097). Following blockade with 5% nonfat dry milk in buffer (Tris-Buffered Saline and Tween 20, TBST),
primary antibodies against α₁D adrenergic receptor (α₁R) (H-142, 1:300, sc-10721, Santa Cruz Biotechnology, Santa Cruz, CA) were applied. β-actin (C4, 1:100, sc-47778, Santa Cruz Biotechnology, Santa Cruz, CA) was used as loading control. Corresponding secondary antibodies were applied at 1:5000 dilution. Antibodies were diluted in TBST. Supersignal West Pico Chemiluminescent substrate (ThermoFisher Scientific, Waltham, MA; #34096) was used for imaging. Molecular weights were estimated by use of an electrophoresis marker (Sigma Aldrich, C1992). Gels were digitized and bands were analyzed by densitometry in ImageJ, and results are reported as ratios of α₁R /β-actin.

D. Immunohistochemistry (IHC) Detection of Arterial α₁ Adrenergic Receptor

Femoral arteries were resected, formalin fixed, and mounted longitudinally for sectioning. 30 µm sections were made along the length of the artery and placed in 10% formalin overnight. Sections were rinsed in distilled water to remove residual formalin. Endogenous peroxidase activity was removed with Bloxall (Vector Laboratories, Burlingame, CA, SP-6000). 2.5% normal horse serum (Vector Laboratories, Burlingame, CA, S-2012) was then used as a blocking reagent followed by primary antibody incubation with α₁D antibody (1:200, sc-10721, Santa Cruz Biotechnology, Santa Cruz, CA) for 90 min. Sections were incubated for 30 min in ImmPRESS anti-rabbit Ig (Vector Laboratories, Burlingame, CA, MP-7401) and ImmPACT DAB (Vector Laboratories, Burlingame, CA, SK-4105) was used for staining. Sections were mounted using Vectamount (Vector Laboratories, Burlingame, CA, H-5000). Bright-field imaging was carried out at 10X objective magnification. Images were digitized to 8-bit format and measurements were taken of smooth muscle regions in each section (6 measurements/image,
10 images/animal). All analysis was performed on ImageJ. Precautions were taken to assure that all IHC steps were carried out under standard conditions to allow quantitative comparison with digital image analysis.

E. Immunocytochemistry of Smooth Muscle Cells Following Rat Plasma Incubation (ICC)

Blood samples from Control (n = 6), HS (n = 6), HS + TXA (n = 6), and HS + Vehicle (n = 6) rats were drawn and blood was centrifuged at 600g for 10 min to achieve plasma separation. Human carotid smooth muscle cells (SMC) (HCTASMC; Cell Applications, San Diego, CA) were cultured in growth medium (311D-250; Cell Applications, San Diego, CA) at 37 °C in an atmosphere of 5% CO₂ and allowed to reach approximately 100% confluence before being exposed to either starvation medium (310-500; Cell Applications, San Diego, CA), or plasma from Control, HS, HS +TXA, or HS + Vehicle animals. SMCs were incubated in the presence of plasma variant or starvation medium for 3 hours at 37°C. Cells were starved in serum free media for 12 h prior to experimentation and plasma samples were diluted in a 1:5 ratio in starvation medium immediately prior to incubation. Added plasma was normalized to volume rather than protein content. Cells were stained as described above for rat femoral artery sections. Images were acquired at 10X objective magnification, digitized to 8-bit format and measurements were taken as the average intensity for individual cells. All analysis was performed on ImageJ. Precautions were taken to assure that all ICC steps were carried out under standard conditions to allow quantitative comparison with digital image analysis.

F. Statistical Analysis
Data are presented as mean ± standard deviation (SD) unless otherwise noted. One-way analysis of variance (ANOVA) was used where appropriate to evaluate the differences between groups with a post-hoc Tukey correction. All analyses were performed using Graphpad (Graphpad Software Inc., La Jolla, CA). A value of p < 0.05 was considered statistically significant for all tests.

RESULTS

A. Blood Pressure Response to Enteral TXA Treatment

All groups subjected to HS were maintained at similar systemic blood pressures during hypovolemia. After return of the shed blood, pressure was transiently restored, before dropping significantly in the HS and HS + Vehicle groups (Figure 1). The animal group treated enterally with TXA (HS + TXA) displayed significantly higher MABP after reperfusion compared to both shock groups.

B. Systemic Vasopressor Response

Vasopressor responsiveness to phenylephrine challenge in vivo during hemorrhagic shock was assessed by ΔMABP and DOR at baseline, and 30, 90 and 120 minutes after the start of reperfusion (Figure 2). There were no significant differences between groups for either ΔMABP or DOR at baseline. At 30 minutes after reperfusion there was a significant decrease in DOR for the HS + Vehicle group (p<0.01) and ΔMABP for both HS and HS + Vehicle groups compared to baseline (p<0.01, 0.0001, respectively) (Figures 3 and 4). This decrement in function in the untreated HS groups continued for the duration of the experiment in both HS and HS + Vehicle
groups (90 min: ΔMABP (p< 0.001, 0.01 respectively), DOR (p< 0.05), and 120 min: ΔMABP (p<0.05, 0.01 respectively), and DOR (p< 0.01)). At no time point during the study did ΔMABP or DOR in the HS + TXA group differ significantly from baseline. Differences in the changes in the AUC (ΔAUC) from baseline (100%) showed a trend towards significance between the HS + Vehicle (26%, p=0.05) and HS groups (37%, p=0.064) vs. HS + TXA (71% of baseline response) at 90 minutes with significant differences between groups at 120 minutes: HS + Vehicle (23%) and HS (26%) vs. HS + TXA (71%, p<0.01 for both groups).

C. α₁ Adrenergic Receptor Levels

The α₁ adrenergic receptor was examined by Western blot to determine whether there were changes in α₁ receptor density in shock and whether these levels were preserved after treatment with enteral TXA. α₁ receptor density was markedly decreased (p<0.01) by HS as measured by Western blot (Figure 5 A) but maintained near Control levels by enteral treatment with TXA. Measurements of α₁ receptor density were confirmed using IHC combined with digital image analysis (Figure 5 C), where receptor levels as detected by immunolabeling were also significantly decreased in HS compared to Control (p < 0.01). Enteral treatment with TXA resulted in light absorbance levels similar to those of the Control group.

D. Human Carotid SMC α₁ Adrenergic Receptor Levels

SMCs were examined for α₁ using ICC (Figure 6). α₁ receptor density was significantly decreased in HS and HS + Vehicle compared to Control groups (p < 0.001, p < 0.05, respectively), while incubation with plasma from the HS + TXA group resulted in levels similar
to Control. $\alpha_1$ receptor levels from the HS + Vehicle and HS groups did not differ significantly from each other.

**DISCUSSION**

Fulminate decompensated hemorrhagic shock (Class IV),\(^{19}\) characterized by limited responsiveness to fluid bolus and vasopressor therapy, carries a poor prognosis, in part because no effective interventions exist. Lack of responsiveness to vasopressors and failure to maintain vascular tone, commonly described in septic shock, are not well documented for hemorrhagic shock, and although several hypotheses have been proposed, there currently exists no consensus as to mechanism.\(^{20}\) To study this problem, we examined the role of the $\alpha_1$ adrenergic receptor in experimental hemorrhagic shock. The $\alpha_1$ receptor is the archetypical adrenergic receptor most responsible for maintaining systemic vascular tone (vasoconstriction) and we hypothesized that failure of this receptor, either through reduced density or function, results in decreased vascular tone and subsequent hemodynamic collapse in hemorrhagic shock.\(^{8}\) Furthermore, we hypothesized that enteral treatment with tranexamic acid (TXA), a mild trypsin inhibitor,\(^{21}\) would lead to improved hemodynamics in hemorrhagic shock, in part by maintaining $\alpha_1$ receptor activity by prevention of proteolytically-mediated processes. The mechanisms of action by which enteral TXA is effective in experimental hemorrhagic shock appears unrelated to TXA’s well-known clinical role as an antifibrinolytic. Although IV TXA has some efficacy in hemorrhagic shock,\(^{16}\) this has not been consistently reported.\(^ {22}\) Other protease inhibitors with differing effects on the coagulation system have also been found to be effective when given enterally to treat experimental shock,\(^{23, 24}\) and the limited patient information on the subject appears to support the
hypothesis that the protease inhibitors must be given enterally to display marked clinical improvement.\textsuperscript{25}

This study confirms previous reports that enteral inhibition with TXA leads to improved hemodynamics in experimental hemorrhagic shock.\textsuperscript{15} Using phenylephrine as a probe for $\alpha_1$ adrenergic receptor responsiveness, we report here that systemic sensitivity to this receptor decreases in experimental hemorrhagic shock with concomitant decrements in systemic pressure maintenance. The decrease in hemodynamic response is manifest as measured by attenuated changes in mean systemic blood pressure ($\Delta$MABP) and in the duration of response (DOR) to the pressor agent phenylephrine, as well as by changes in the total hemodynamic effectiveness of phenylephrine ($\Delta$AUC). This reduction in hemodynamic responsiveness begins early in the reperfusion period and continues unabated through the end of the experiment. Western blot analysis and IHC confirm decreased $\alpha_1$ adrenergic receptor density in hemorrhagic shock; the decrement in density appears to be a mechanism by which $\alpha_1$ receptor-mediated hyporesponsiveness is mediated. This result is consistent with reports from other investigators on adrenergic function in shock, which appears to be predominantly related to changes in receptor density rather than function.\textsuperscript{26}

The mechanisms by which vascular $\alpha_1$ adrenergic receptor density is modulated in shock are unknown, but results from our study demonstrate that circulating factors in the blood may be operant. These circulating mediators may include digestive pancreatic proteases\textsuperscript{15} and products of proteolysis that either directly,\textsuperscript{27} or indirectly through vasoactive degradation products\textsuperscript{14} affect receptor function, and thus vascular responsiveness. Supporting this hypothesis are our current findings that enteral TXA restores receptor levels to baseline concentrations with commensurate improvements in hemodynamics in experimental hemorrhagic shock by protecting the ischemic
small bowel from proteolytic degradation;\textsuperscript{11, 12, 15} this protection is not seen with intravenous protease inhibitor treatment.\textsuperscript{28}

There are several limitations to this study. Among these is the lack of a detailed described mechanism by which enteral TXA inhibition in the bowel restores $\alpha_1$ receptor function systemically. Previous studies have demonstrated increased survival after experimental shock with enteral protease inhibition,\textsuperscript{15} but not with intravenous protease inhibition.\textsuperscript{28, 29} The reasons for this are two-fold: first, the high concentrations of proteolytic enzymes in the bowel (millimolar range) can only be overcome by high concentrations of inhibitor in the bowel lumen, which is not feasible in the systemic circulation. Second, and more importantly, by limiting proteolytic degradation of the bowel mucosa and resulting permeability changes,\textsuperscript{13, 17, 18, 30} enteral protease inhibition prevents the systemic egress of non-protease gut mediators that might otherwise affect $\alpha_1$ receptor function and result in subsequent hypotension. Further studies are necessary to identify the mediators and mechanisms responsible for this phenomenon. Likewise, although changes in $\alpha_1$ receptor responsiveness appear to be secondary to changes in density as shown by Western blot and IHC analysis, the possibility of abnormal $\alpha_1$ receptor binding or malfunction in hemorrhagic shock cannot be excluded. Finally, it is acknowledged that other receptors, both adrenergic (e.g., $\beta_1$, $\beta_2$) and otherwise (e.g., vasopressin), are also operant and may be affected in hemorrhagic shock; further studies are necessary to clarify the roles of these receptors in this condition and the possible effect of enteral TXA in modulating them.

In conclusion, this study proposes a possible mechanism for vasopressor resistance-induced refractory shock by demonstrating that hemorrhagic shock decreases $\alpha_1$ adrenergic receptor responsiveness and density. Decrements in $\alpha_1$ adrenergic receptor activity and concentrations are mitigated by enteral treatment with TXA, with resultant improved
hemodynamics and vascular responsiveness. Restoration of $\alpha_1$ receptor density and functionality may be a key mechanism by which enteral TXA improves systemic blood pressure and survival in experimental hemorrhagic shock.

**AUTHOR CONTRIBUTION STATEMENT**

MS, FA, JBL, AT, MC, and JL participated in data acquisition, analysis and experimental design; FA, GWS and EBK participated in experimental design, data analysis, data interpretation and drafting of the manuscript.
REFERENCES


FIGURE LEGENDS

Figure 1
Mean arterial blood pressure (MABP) of Control, Hemorrhagic Shock (HS), Hemorrhagic Shock + Enteral Tranexamic Acid (HS + TXA), and Hemorrhagic Shock + Vehicle (HS + Vehicle) groups. MABP was decreased to a mean of 35 mmHg over several minutes by the serial withdrawal of small aliquots of blood (0.5 ml/min). Reperfusion was carried out in analogous fashion by slow reinfusion of shed blood (0.5 ml/min). **p < 0.01 Control vs. HS + TXA and #p < 0.0001 HS, HS + Vehicle vs. HS + TXA and Control; #p < 0.0001 Control vs. HS, HS + Vehicle, HS + TXA during ischemia period as per experimental design. There were no statistical differences between HS and HS + Vehicle groups at any time points. Results shown as Mean ± SD.

Figure 2
Representative hemodynamic response to phenylephrine challenge (ΔMABP) at 120 min after start of reperfusion for a single animal in each group.

Figure 3
(A) Average absolute change in MABP (ΔMABP) per group over time in response to phenylephrine challenge (Mean ± SD). (B) ΔMABP response to phenylephrine challenge 30 min after start of reperfusion, (C) ΔMABP response to phenylephrine challenge 90 min after start of reperfusion, (D) ΔMABP response to phenylephrine challenge 120 min after start of reperfusion. *p < 0.05 Control vs. HS, **p < 0.01 Control vs. HS, HS + Vehicle, ***p < 0.001 Control vs. HS, ****p < 0.0001 Control vs HS + Vehicle. Results plotted as Mean ± SD.

Figure 4
(A) Average response duration to phenylephrine challenge (DOR) per group over time (Mean ± SD). (B) DOR to phenylephrine challenge 30 min after start of reperfusion, (C) DOR to phenylephrine challenge 90 min after start of reperfusion, (D) DOR to phenylephrine challenge 120 min after start of reperfusion. *p < 0.05 Control vs. HS, HS + Vehicle, **p < 0.01 Control vs. HS, HS + Vehicle. Results plotted as Mean ± SD.

Figure 5
(A) α₁D renal artery band density by Western blot with representative α₁D renal artery band (α-1 AR). The average of the control band densities was used as a reference. β-actin is shown as a loading control for the same animals. (B) Histogram of the average relative band intensities per
group expressed as ratios of $\alpha_1R/\beta$-actin (n=6 animals/group). *p < 0.05, HS vs. HS + TXA; **p < 0.01, Control vs. HS. Results plotted as Mean ± SD. (C) Representative femoral artery sections labeled for $\alpha_{1D}$. Insets indicate sample smooth muscle regions of interest (squared boxes) both before and after 8-bit conversion. (D) Histogram of labeling density values in digital units. Scale bar is = 100 microns. **p < 0.01 Control vs. HS, *p<0.05 HS + TXA vs all other groups. Results plotted as Mean ± SD.

**Figure 6**

(A) Human carotid SMCs labeled for $\alpha_{1D}$ adrenergic receptor following 3 hour incubation with rat plasma, normalized with respect to added plasma volume. Histograms display labeling density values in digital units. Scale bar is = 10 microns. *p<0.05 Control vs. HS + Vehicle, ***p < 0.001 Control vs. HS, ***p<0.001 HS + TXA vs. HS + Vehicle, ****p<0.0001 HS + TXA vs. HS. Results plotted as Mean ± SD.
Figure 3

(A) Graph showing the change in MAP (ΔMAP) over different time periods (30 Min, 90 Min, 120 Min) for different conditions: Control, HS, HS + TXA, and HS + Vehicle. The y-axis represents ΔMAP (mmHg) and the x-axis represents the reperfusion period in minutes. The graph indicates a significant decrease in MAP over time, with differences between the groups.

(B) Bar graph for 30 min reperfusion period showing ΔMAP for Control, HS, HS + TXA, and HS + Vehicle. The bars are labeled with statistical significance (*** for P < 0.001, ** for P < 0.01).

(C) Bar graph for 90 min reperfusion period showing ΔMAP for Control, HS, HS + TXA, and HS + Vehicle. The bars are labeled with statistical significance (*** for P < 0.001, ** for P < 0.01).

(D) Bar graph for 120 min reperfusion period showing ΔMAP for Control, HS, HS + TXA, and HS + Vehicle. The bars are labeled with statistical significance (*) for P < 0.05 and (**) for P < 0.01.)
Figure 4

(A) Graph showing the change in DOR (sec) over the reperfusion period (min) for different groups: Control, HS, HS + TXA, and HS + Vehicle. The graph indicates that the HS + TXA group has a lower DOR compared to the other groups.

(B) Bar graph showing the DOR (sec) at 30 min for Control, HS, HS + TXA, and HS + Vehicle. The HS + TXA group has the lowest DOR.

(C) Bar graph showing the DOR (sec) at 90 min for Control, HS, HS + TXA, and HS + Vehicle. The HS + TXA group has the lowest DOR.

(D) Bar graph showing the DOR (sec) at 120 min for Control, HS, HS + TXA, and HS + Vehicle. The HS + TXA group has the lowest DOR.
Figure 5

(A) Western blot analysis showing the expression of α-1 AR (approx. 60 kDa) and β-actin (approx. 42 kDa) in Control, HS, and HS + TXA groups.

(B) Bar graph depicting the proportion of α-1 AR/β-actin (AU) in Control, HS, and HS + TXA groups. Statistical significance: *p < 0.05, **p < 0.01.

(C) Immunohistochemical staining of Control, HS, HS + TXA, and HS + Vehicle groups.

(D) Absorption measurement in Digital Units for Control, HS, HS + TXA, and HS + Vehicle groups. Statistical significance: *p < 0.05, **p < 0.01.
Figure 6

(A) Control, HS, HS + TXA, HS + Vehicle

(B) Absorption (Digital Units)

Control, HS, HS + TXA, HS + Vehicle